Jiangxi XinGanjiang Pharmaceutical Co., Ltd. (stock code: 873167) was established in 2004 and was listed on the Beijing Stock Exchange in 2023. With a registered capital of 70.86 million yuan, it is a national high-tech enterprise. The company focuses on the research, production and sales of raw materials, chemical drug preparations and traditional Chinese medicines. Its core products include glucose acid salt series raw materials (such as calcium gluconate), vitamin C chewable tablets, cold relief capsules and heart and brain health capsules, etc. It holds a leading market share in the industry. The company attaches great importance to research and development innovation, with 22 technical personnel and 14 ongoing projects, covering areas such as cardiovascular and cerebrovascular diseases, colds, and vitamins. It also collaborates with external institutions to enhance its research capabilities. 

One of its subsidiaries, Jiangxi Zhongyuan Pharmaceutical Co., Ltd., was transformed from the large-scale traditional Chinese medicine state-owned enterprise "Jiangxi Ji'an Pharmaceutical Factory" established in 1958. It is a well-established and deeply rooted Chinese patent medicine manufacturer with a long history and rich traditional Chinese medicine culture. The company covers an area of 30,000 square meters and is equipped with seven production lines for pills, syrups, wine, decoctions, ointments, liniments, and syrups. Its core products include "Ajiao Blood-Tonifying Ointment", "Erbao Ointment", "Wuji Bai Feng Pills", etc. The distinctive "Qishe Medicine Wine" has been recognized as a national and Jiangxi provincial intangible cultural heritage. Zhongyuan adheres to the concept of "Inheritance and Authenticity", strictly selects raw materials and strives for excellence in production. With high-quality and effective products, it sincerely cooperates with customers and develops together with them.